KLP Kapitalforvaltning AS bought a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 18,000 shares of the company's stock, valued at approximately $1,406,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the third quarter worth about $620,000. Citigroup Inc. increased its stake in Prestige Consumer Healthcare by 66.6% during the 3rd quarter. Citigroup Inc. now owns 76,772 shares of the company's stock worth $5,535,000 after buying an additional 30,677 shares during the period. Cerity Partners LLC lifted its holdings in Prestige Consumer Healthcare by 103.9% during the 3rd quarter. Cerity Partners LLC now owns 6,347 shares of the company's stock worth $458,000 after buying an additional 3,234 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Prestige Consumer Healthcare by 276.2% in the third quarter. BNP Paribas Financial Markets now owns 17,379 shares of the company's stock worth $1,253,000 after acquiring an additional 12,759 shares in the last quarter. Finally, Martingale Asset Management L P grew its stake in shares of Prestige Consumer Healthcare by 0.4% in the third quarter. Martingale Asset Management L P now owns 36,971 shares of the company's stock worth $2,666,000 after acquiring an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.
Insider Buying and Selling
In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
PBH has been the subject of a number of recent research reports. DA Davidson lifted their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research note on Thursday, December 19th. Finally, Royal Bank of Canada increased their price objective on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a "sector perform" rating in a research report on Friday, March 21st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Prestige Consumer Healthcare has an average rating of "Moderate Buy" and an average target price of $93.33.
Read Our Latest Stock Report on PBH
Prestige Consumer Healthcare Stock Down 1.7 %
Shares of NYSE:PBH traded down $1.49 during trading on Thursday, hitting $84.54. 447,230 shares of the company were exchanged, compared to its average volume of 275,366. The firm's 50 day moving average price is $83.91 and its 200-day moving average price is $79.34. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $90.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock has a market capitalization of $4.19 billion, a P/E ratio of 19.80, a PEG ratio of 2.69 and a beta of 0.46.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. On average, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Articles
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
